IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
IPCALAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.7 pts less than Nifty Midcap 150 and 3.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ipca Laboratories reported strong Q1 FY26 results. Standalone revenue from operations grew about 12% year-on-year to Rs 1,746.90 crore, while consolidated revenue rose 11% to Rs 2,308.85 crore. Standalone net profit jumped 28% to Rs 262.04 crore (EPS of Rs 10.33 vs Rs 8.05), and consolidated net profit grew 18% to Rs 234.42 crore. Standalone EBITDA margin expanded to 23.82% from 22.25% a year ago, aided by 18% growth in export income to Rs 699.76 crore and 10% growth in domestic formulations to Rs 961.01 crore. The quarter had no exceptional items, though the prior year had included Rs 281.54 crore in impairment charges against a US subsidiary and an associate. The auditor issued an unmodified limited review report.
Positive quarter with double-digit revenue growth, healthy margin expansion on a standalone basis, and over 25% jump in standalone profit, likely to support investor sentiment. The newly acquired Unichem Ireland subsidiary has no impact on the current quarter numbers.